If not, you might want to consider adding to your "must-test-drive" list, as even we were largely impressed by the 2024 ...
Wave Life Sciences (WVE) stock rises on plans to file for FDA accelerated approval of WVE-N531 in 2026, targeting Duchenne muscular dystrophy. Read more here.